The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients.
 
Natalie F. Uy
No Relationships to Disclose
 
Micah Tratt
Stock and Other Ownership Interests - Amgen
 
Keith D. Eaton
Research Funding - Mirati Therapeutics (Inst)
 
Rafael Santana-Davila
Consulting or Advisory Role - AstraZeneca; EMD Serono; Mirati Therapeutics
Research Funding - ALX Oncology (Inst); BeyondSpring Pharmaceuticals (Inst); Genentech (Inst); ISA Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
Christina S Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Guardant Health; Janssen; Pfizer; Regeneron; Silverback Therapeutics; Takeda; Turning Point Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Spectrum Pharmaceuticals (Inst); TP Therapeutics (Inst)